Abstract
We studied the effect of high-dose mouse IgG on TMEV-induced demyelinating disease (TMEV-IDD). We injected TMEV intracerebrally into susceptible SJL/J mice and induced TMEV-IDD. Mouse IgG were injected intraperitonealy, and clinical course and various immunological indicators were studied. The results show that TMEV-IDD was significantly suppressed both clinically and histologically (P<0.01) when IgG were administered in the effector phase. The delayed type hypersensitivity and T cell proliferative response specific for TMEV were decreased by this treatment. In an ELISPOT assay, the number of TNF-α producing lymphocytes in the spinal cords was low in high-dose IgG treated mice compared with PBS treated control mice. These data suggest that administration of IgG suppresses TMEV-IDD and may be promising treatment to prevent exacerbation of human multiple sclerosis. Copyright (C) 2000 Elsevier Science B.V.
Original language | English (US) |
---|---|
Pages (from-to) | 22-28 |
Number of pages | 7 |
Journal | Journal of Neuroimmunology |
Volume | 108 |
Issue number | 1-2 |
DOIs | |
State | Published - Aug 1 2000 |
Keywords
- Demyelination
- High-dose immunoglobulion therapy
- Multiple sclerosis
- Theiler's murine encephalomyelitis virus
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
- Immunology and Allergy
- Immunology